Turing gets go-ahead for Phase I trial; Oasmia prices downsized IPO;

@FierceBiotech: Merrimack wins expedited FDA OK for pancreatic cancer drug Onivyde. Report | Follow @FierceBiotech

@JohnCFierce: The $NK market cap is down to a meager $873M, debuted at $2.6B -- Still too much? Soon-Shiong magic sparkles not so shiny? | Follow @JohnCFierce

@DamianFierce: So I guess $SHPG's Lumena buyout didn't go so well. Story | More | Follow @DamianFierce

> The FDA signed off on Turing Pharmaceuticals' plan to take its drug for a rare epileptic disorder into Phase I, granting fast-track status to the program. More

> Oasmia Pharmaceutical raised $9 million in an IPO, pricing below its expected range. News

> GlaxoSmithKline ($GSK) CEO Andrew Witty said his company's focus on low-margin therapeutic areas will insulate it from the pricing controversy now raging in the U.S. Story

Medical Device News

@FierceMedDev: Check out this year's Fierce 15: The new strategic med tech mania sets the stage for 2015's Fierce 15. Feature | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Silk Road reels in $57M to commercialize its system for stroke prevention. Article | Follow @VarunSaxena2

@EmilyWFierce: Dx Digest: Roche notches molecular diagnostics sales win; Veracyte CEO lambastes CMS pricing proposals. Report | Follow @EmilyWFierce

> Congressman to introduce bill banning Bayer's Essure contraceptive device. More

> Swiss scientists reveal miniaturized patient monitoring device for ICU. Story

Pharma News

@FiercePharma: Asia's dengue epidemic highlights race for treatment, vaccine options. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: Japan's  says its mAb work with  means a need for a $309M API plant expansion. FiercePharmaManufacturing news | Follow @EricPFierce

@CarlyHFierce: : We did an episode of @FierceBiotech Radio on biopharma's wacky Wednesday. More | Follow @CarlyHFierce

> Novartis wins European recs for a pair of new Cosentyx uses. Item

> Shire's not giving up on target Baxalta, it says amid Q3 beat. Article

Suggested Articles

A new clinical hold is the latest setback for Solid Biosciences and the development of its gene therapy for Duchenne muscular dystrophy.

VBI's Sci-B-Vac protected twice as many people than GSK's Engerix-B did after the second dose.

The notice comes weeks after Amgen revealed it was retreating from its East Coast neuroscience operations.